Sinovac’s Vaccine Efficacy Less Than 60% in Brazil Trial -Report

Brazilian news website UOL reported that the efficacy rate that Butantan was set to announce on Tuesday was between 50% and 60% — above the threshold set by health regulators, but well below the numbers celebrated last week.

RIO DE JANEIRO, BRAZIL - The coronavirus vaccine developed by China’s Sinovac Biotech showed a general efficacy of less than 60% in its late-stage trial in Brazil, a news website reported on Monday, citing two people who seen the results.

Sao Paulo’s Butantan biomedical center, which partnered with Sinovac to test and produce the vaccine in Brazil, dismissed the report as “purely speculative” as it prepares to release a more complete set of results on Tuesday at 12:45 p.m. (1545 GMT).

Medical experts and regulators criticized what they called an incomplete disclosure of study results last . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?